Floatz logo

Evomela

Non-malignant Disorders

Washington University School of MedicinePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Non-malignant Disorders cohort.

Asset / SponsorPhaseRating
Thiotepa
Washington University School of Medicine
Phase 1/2CCC
Monomethyl Fumarate
Washington University School of Medicine
Phase 1/2CCC
METHOTREXATE
Washington University School of Medicine
Phase 1/2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Washington University School of Medicine
Phase 1/2CCC
Fludarabine
Washington University School of Medicine
Phase 1/2CCC
CYCLOSPORIN A
Washington University School of Medicine
Phase 1/2CCC
Hydroxyurea
Washington University School of Medicine
Phase 1/2CCC

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →